General justification in terms of effectiveness and toxicities for the use of nanocarriers
Source abstract
Abstract
This review highlights the potential benefits and drawbacks of using nanocarriers as drug delivery systems. Nanocarriers have been widely utilized to enhance drug efficiency, overcome drug resistance, and reduce adverse effects. However, the interaction between nanocarriers and biological systems can lead to toxic responses. Therefore, it is crucial to carefully select optimized nanocarriers to minimize toxicity and maximize efficiency. Every type of nanocarrier has its own advantages and disadvantages. Hybrid nanocarriers have been engineered to address the limitations of existing nanocarriers and are considered more suitable for developing new formulations. The article discusses various aspects of nanocarriers, including their applicability, potential toxicity, and strategies for utilizing appropriate nanocarriers in nanoformulations. To mitigate the toxicity of nanocarriers, several approaches can be employed, such as PEGylation, coating, charge coating, and injections of free PEG; moreover, by modifying the preparation method or utilizing hybrid nanocarriers, the efficiency of drug delivery systems can be improved. Overall, the article emphasizes the importance of selecting appropriate nanocarriers and employing strategies to reduce toxicity while enhancing drug delivery efficiency.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Dunne S et al (2013) A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacol Toxicol 14(1):110.1186/2050-6511-14-1 ↗
2. Patra JK et al (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16(1):7110.1186/s12951-018-0392-8 ↗
3. Oroojalian F et al (2020) Recent advances in nanotechnology-based drug delivery systems for the kidney. J Control Release 321:442–46210.1016/j.jconrel.2020.02.027 ↗
4. Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3(1):16–2010.1021/nn900002m ↗
5. Bozzuto G, Molinari A (2015) Liposomes as nanomedical devices. Int J Nanomedicine 10:975–99910.2147/IJN.S68861 ↗
6. Hines DJ, Kaplan DL (2013) Poly (lactic-co-glycolic) acid− controlled-release systems: experimental and modeling insights. Crit Rev Ther Drug Carrier Syst 30(3):257–7610.1615/CritRevTherDrugCarrierSyst.2013006475 ↗
7. Kesharwani P et al (2014) Dendrimer as nanocarrier for drug delivery. Prog Polym Sci 39(2):268–30710.1016/j.progpolymsci.2013.07.005 ↗
8. Dang Y, Guan J (2020) Nanoparticle-based drug delivery systems for cancer therapy. Smart Materials in Medicine 1:10–1910.1016/j.smaim.2020.04.001 ↗
9. Klibanov AL et al (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268(1):235–23710.1016/0014-5793(90)81016-H ↗
10. Bulbake U et al (2017) Liposomal formulations in clinical use: an updated review. Pharmaceutics 9(2):1210.3390/pharmaceutics9020012 ↗
11. Li Z et al (2017) Cancer drug delivery in the nano era: An overview and perspectives. Oncol Rep 38(2):611–62410.3892/or.2017.5718 ↗
12. Prasad M et al (2018) Nanotherapeutics: an insight into healthcare and multi-dimensional applications in medical sector of the modern world. Biomed Pharmacother 97:1521–153710.1016/j.biopha.2017.11.026 ↗
13. Bhardwaj V et al (2019) Recalcitrant Issues and New Frontiers in Nano-Pharmacology. Front Pharmacol 10:136910.3389/fphar.2019.01369 ↗
14. Farjadian F et al (2019) Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine 14(1):93–12610.2217/nnm-2018-0120 ↗
15. Badea N et al (2020) Systems based on carbon nanotubes with potential in cancer therapy. Mater Chem Phys 241:12243510.1016/j.matchemphys.2019.122435 ↗
16. Vakhshiteh F et al (2020) Peptide-conjugated liposomes for targeted miR-34a delivery to suppress breast cancer and cancer stem-like population. J Drug Delivery Sci Technol 5710.1016/j.jddst.2020.101687 ↗
17. Keshtiara P et al (2020) New dendrimers containing ruthenium nanoparticles as catalysts for hydrogenation of citral to 3, 7-dimethyloctanol. Mater Chem Phys 24910.1016/j.matchemphys.2020.122962 ↗
18. Moghimipour E et al (2013) Solid lipid nanoparticles as a delivery system for Zataria multiflora essential oil: formulation and characterization. Curr Drug Deliv 10(2):151–15710.2174/1567201811310020001 ↗
19. Kaur G et al (2016) Archaeosomes: an excellent carrier for drug and cell delivery. Drug Deliv 23(7):2497–251210.3109/10717544.2015.1019653 ↗
20. Zylberberg C, Matosevic S (2016) Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Deliv 23(9):3319–332910.1080/10717544.2016.1177136 ↗
21. Handali S et al (2019) Co-delivery of 5-fluorouracil and oxaliplatin in novel poly (3-hydroxybutyrate-co-3-hydroxyvalerate acid)/poly (lactic-co-glycolic acid) nanoparticles for colon cancer therapy. Int J Biol Macromol 124:1299–131110.1016/j.ijbiomac.2018.09.119 ↗
22. Jiang T et al (2020) Recent advances in encapsulation of curcumin in nanoemulsions: A review of encapsulation technologies, bioaccessibility and applications. Food Res Int 13210.1016/j.foodres.2020.109035 ↗
23. Sett R et al (2020) Effect of temperature and salts on niosome-bound anti-cancer drug along with disruptive influence of cyclodextrins. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 23410.1016/j.saa.2020.118261 ↗
24. Shah S et al (2020) Nanogels as drug Carriers-Introduction, chemical Aspects, release mechanisms and potential Applications. Int J Pharm 15. https://doi.org/10.1016/j.ijpharm.2020.11926810.1016/j.ijpharm.2020.119268 ↗
25. Peng Y et al (2020) Research and development of drug delivery systems based on drug transporter and nano-formulation. Asian J Pharm Sci 15(2):220–236. https://doi.org/10.1016/j.ajps.2020.02.00410.1016/j.ajps.2020.02.004 ↗
26. Silva AH et al (2014) Solid lipid nanoparticles induced hematological changes and inflammatory response in mice. Nanotoxicology 8(2):212–21910.3109/17435390.2013.782076 ↗
27. Lee JS et al (2010) Thermosensitive hydrogel-containing polymersomes for controlled drug delivery. J Control Release 146(3):400–40810.1016/j.jconrel.2010.06.002 ↗
28. Aibani N et al (2020) Liposome mimicking polymersomes; A comparative study of the merits of polymersomes in terms of formulation and stability. Int J Pharm : X 2:100040
29. Toh M-R, Chiu GN (2013) Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing. Asian J Pharm Sci 8(2):88–9510.1016/j.ajps.2013.07.011 ↗
30. Zavec AB et al (2014) Archaeosomes can efficiently deliver different types of cargo into epithelial cells grown in vitro. J Biotechnol 192:130–13510.1016/j.jbiotec.2014.09.015 ↗
31. Atallah C et al (2020) Development of cysteamine loaded liposomes in liquid and dried forms for improvement of cysteamine stability. Int J Pharm 15(589). https://doi.org/10.1016/j.ijpharm.2020.11972110.1016/j.ijpharm.2020.119721 ↗
32. Salvi VR, Pawar P (2019) Nanostructured lipid carriers (NLC) system: a novel drug targeting carrier. J Drug Deliv Sci Technol 7(1):41–55
33. Karmakar G et al (2018) Role of PEG 2000 in the surface modification and physicochemical characteristics of pyrazinamide loaded nanostructured lipid carriers. J Chem Sci 130(4):4210.1007/s12039-018-1448-x ↗
34. Müller RH (2007) Lipid nanoparticles: recent advances. Adv Drug Deliv Rev 59(6):522–30. https://doi.org/10.1016/j.addr.2007.04.01210.1016/j.addr.2007.04.012 ↗
35. Zhou X et al (2018) Nano-formulations for transdermal drug delivery: a review. Chin Chem Lett 29(12):1713–172410.1016/j.cclet.2018.10.037 ↗
36. Shah SM et al (2015) LeciPlex, invasomes, and liposomes: A skin penetration study. Int J Pharm 490(1-2):391–40310.1016/j.ijpharm.2015.05.042 ↗
37. Amnuaikit T et al (2018) Vesicular carriers containing phenylethyl resorcinol for topical delivery system; liposomes, transfersomes and invasomes. Asian J Pharm Sci 13(5):472–48410.1016/j.ajps.2018.02.004 ↗
38. Zheng C, Lü FL (2013) The Virosome as a Novel Concept for High Pathogenic Porcine Reproductive and Respiratory Syndrome Virus (HP-PRRSV) Vaccines. J Integr Agric 12(7):1215–122410.1016/S2095-3119(13)60440-2 ↗
39. Pöltl-Frank F et al (1999) Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine. Clin Exp Immunol 117(3):49610.1046/j.1365-2249.1999.00989.x ↗
40. Moussaoui N et al (2002) Marinosomes®, marine lipid-based liposomes: physical characterization and potential application in cosmetics. Int J Pharm 242(1-2):361–36510.1016/S0378-5173(02)00217-X ↗
41. Cansell MS et al (2007) Prostaglandin E2 and interleukin-8 production in human epidermal keratinocytes exposed to marine lipid-based liposomes. Int J Pharm 343(1-2):277–28010.1016/j.ijpharm.2007.04.014 ↗
42. Paleos CM et al (2013) Formation of artificial multicompartment vesosome and dendrosome as prospected drug and gene delivery carriers. J Control Release 170(1):141–15210.1016/j.jconrel.2013.05.011 ↗
43. Mishra DK et al (2018) Lipid based nanocarriers: a translational perspective. Nanomedicine 14(7):2023–205010.1016/j.nano.2018.05.021 ↗
44. Lu M et al (2018) Comparison of exosome-mimicking liposomes with conventional liposomes for intracellular delivery of siRNA. Int J Pharm 550(1-2):100–11310.1016/j.ijpharm.2018.08.040 ↗
45. Stremersch S et al (2016) Comparing exosome-like vesicles with liposomes for the functional cellular delivery of small RNAs. J Control Release 232:51–6110.1016/j.jconrel.2016.04.005 ↗
46. Donoso-Quezada J et al (2019) Exosomes as nanocarriers for the delivery of bioactive compounds from black bean extract with antiproliferative activity in cancer cell lines. Mater Today: Proc 13:362–36910.1016/j.matpr.2019.03.166 ↗
47. Niu X et al (2019) Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances. Asian J Pharm Sci 14(5):480–49610.1016/j.ajps.2018.09.005 ↗
48. Shi H et al (2020) Folate decorated polymeric micelles for targeted delivery of the kinase inhibitor dactolisib to cancer cells. Int J Pharm 30(582)10.1016/j.ijpharm.2020.119305 ↗
49. Sorasitthiyanukarn FN et al (2018) Chitosan/alginate nanoparticles as a promising approach for oral delivery of curcumin diglutaric acid for cancer treatment. Mater Sci Eng C 93:178–19010.1016/j.msec.2018.07.069 ↗
50. Saralkar P, Dash AK (2017) Alginate nanoparticles containing curcumin and resveratrol: preparation, characterization, and in vitro evaluation against DU145 prostate cancer cell line. AAPS PharmSciTech 18(7):2814–282310.1208/s12249-017-0772-7 ↗
51. Sosnik A (2014) Alginate particles as platform for drug delivery by the oral route: state-of-the-art. Int Scholarly Res Notices 20142014(2014)10.1155/2014/926157 ↗
52. Moghimipour E et al (2014) Archaeosomes as means of nano-drug delivery. Rev Med Microbiol 25(2):40–4510.1097/MRM.0000000000000000 ↗
53. Li Z et al (2010) Investigation of archaeosomes as carriers for oral delivery of peptides. Biochem Biophys Res Commun 394(2):412–41710.1016/j.bbrc.2010.03.041 ↗
54. Agbayani G et al (2020) Mechanistic insight into the induction of cellular immune responses by encapsulated and admixed archaeosome-based vaccine formulations. Hum Vaccin Immunother 16(9):2183–2195. https://doi.org/10.1080/21645515.2020.178830010.1080/21645515.2020.1788300 ↗
55. Le Meins J-F et al (2011) Recent trends in the tuning of polymersomes’ membrane properties. Euro Phys J E 34(2):1–1710.1140/epje/i2011-11014-y ↗
56. Poma A et al (2018) Polymersomes: Synthesis and Applications. In: Encyclopedia of Polymer Science and Technology, pp 1–43
57. Pan XQ et al (2019) Folate-conjugated pluronic/polylactic acid polymersomes for oral delivery of paclitaxel. Int J Biol Macromol 139:377–38610.1016/j.ijbiomac.2019.07.224 ↗
58. Pink DL et al (2019) On the structure of solid lipid nanoparticles. Small 15(45):190315610.1002/smll.201903156 ↗
59. Johnsen KB et al (2014) A comprehensive overview of exosomes as drug delivery vehicles—endogenous nanocarriers for targeted cancer therapy. Biochimica et Biophysica Acta (BBA)-Rev Cancer 1846(1):75–8710.1016/j.bbcan.2014.04.005 ↗
60. Kisak E et al (2004) The vesosome-A multicompartment drug delivery vehicle. Curr Med Chem 11(2):199–21910.2174/0929867043456197 ↗
61. Ibrahim S et al (2018) Curcumin marinosomes as promising nano-drug delivery system for lung cancer. Int J Pharm 540(1-2):40–4910.1016/j.ijpharm.2018.01.051 ↗
62. Dey M et al (2019) Breaking the barricade of oral chemotherapy through polysaccharide nanocarrier. Int J Biol Macromol 1(130):34–49. https://doi.org/10.1016/j.ijbiomac.2019.02.09410.1016/j.ijbiomac.2019.02.094 ↗
63. McCluskie MJ et al (2017) Sulfated archaeal glycolipid archaeosomes as a safe and effective vaccine adjuvant for induction of cell-mediated immunity. Hum Vaccin Immunother 13(12):2772–277910.1080/21645515.2017.1316912 ↗
64. Moghimipour E et al (2013) The potent in vitro skin permeation of archaeosome made from lipids extracted of Sulfolobus acidocaldarius. Archaea 201310.1155/2013/782012 ↗
65. Muñoz-Juan A et al (2019) Latest Advances in the Development of Eukaryotic Vaults as Targeted Drug Delivery Systems. Pharmaceutics 11(7):30010.3390/pharmaceutics11070300 ↗
66. Yang J et al (2013) Vault nanoparticles engineered with the protein transduction domain, TAT48, enhances cellular uptake. Integr Biol 5(1):151–15810.1039/c2ib20119d ↗
67. Casañas A et al (2012) Vault particles: a new generation of delivery nanodevices. Curr Opin Biotechnol 23(6):972–97710.1016/j.copbio.2012.05.004 ↗
68. Romana B et al (2020) A liposome-micelle-hybrid (LMH) oral delivery system for poorly water-soluble drugs: Enhancing solubilisation and intestinal transport. Eur J Pharm Biopharm 154:338–34710.1016/j.ejpb.2020.07.022 ↗
69. Hadinoto K et al (2013) Lipid–polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 85(3):427–44310.1016/j.ejpb.2013.07.002 ↗
70. Emami F et al (2019) Poly (lactic acid)/poly (lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery. J Pharm Investig 1–1630(3):257–76
71. Sur S et al (2019) Recent developments in functionalized polymer nanoparticles for efficient drug delivery system. Nano-Structures Nano-Objects 20:10039710.1016/j.nanoso.2019.100397 ↗
72. Cheow WS, Hadinoto K (2011) Factors affecting drug encapsulation and stability of lipid–polymer hybrid nanoparticles. Colloids Surf B: Biointerfaces 85(2):214–22010.1016/j.colsurfb.2011.02.033 ↗
73. Ghitman J et al (2020) Review of hybrid PLGA nanoparticles: Future of smart drug delivery and theranostics medicine. Mater Des 193(1)10.1016/j.matdes.2020.108805 ↗
74. Macedo AS et al (2020) Novel and revisited approaches in nanoparticle systems for buccal drug delivery. J Control Release 10(320):125–141. https://doi.org/10.1016/j.jconrel.2020.01.00610.1016/j.jconrel.2020.01.006 ↗
75. ud Din, F. et al (2017) Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine 12:729110.2147/IJN.S146315 ↗
76. Behzadi S et al (2017) Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev 46(14):4218–424410.1039/C6CS00636A ↗
77. Wang H et al (2018) The protein corona on nanoparticles as viewed from a nanoparticle-sizing perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 10(4):e150010.1002/wnan.1500 ↗
78. Blanco E et al (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33(9):94110.1038/nbt.3330 ↗
79. Qie Y et al (2016) Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Sci Rep 6(1):1–1110.1038/s41598-016-0001-8 ↗
80. Li H et al (2019) Size Dependency of Circulation and Biodistribution of Biomimetic Nanoparticles: Red Blood Cell Membrane-Coated Nanoparticles. Cells 8(8):88110.3390/cells8080881 ↗
81. Rayamajhi S et al (2020) pH-responsive cationic liposome for endosomal escape mediated drug delivery. Colloids Surf B: Biointerfaces 188:11080410.1016/j.colsurfb.2020.110804 ↗
82. Nogueira E et al (2015) Design of liposomal formulations for cell targeting. Colloids Surf B Biointerfaces 136:514–52610.1016/j.colsurfb.2015.09.034 ↗
83. Nair KL et al (2011) Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int J Nanomedicine 6:1685–1697
84. Yang W et al (2018) Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer. Mater Sci Eng C 89:328–33510.1016/j.msec.2018.04.011 ↗
85. Handali S et al (2019) New folate receptor targeted nano liposomes for delivery of 5-fluorouracil to cancer cells: Strong implication for enhanced potency and safety. Life Sci 227:39–5010.1016/j.lfs.2019.04.030 ↗
86. Chen J et al (2016) Nanostructured glycopolymer augmented liposomes to elucidate carbohydrate-mediated targeting. Nanomedicine 12(7):2031–204110.1016/j.nano.2016.05.001 ↗
87. Moghimipour E et al (2018) A mechanistic study of the effect of transferrin conjugation on cytotoxicity of targeted liposomes. J Microencapsul 35(6):548–55810.1080/02652048.2018.1547325 ↗
88. Calori IR et al (2020) Determination of critical micelle temperature of Pluronics® in Pluronic/gel phase liposome mixtures using steady-state anisotropy. J Mol Liq 30410.1016/j.molliq.2020.112784 ↗
89. Ge P et al (2020) Enhanced cancer therapy of celastrol in vitro and in vivo by smart dendrimers delivery with specificity and biosafety. Chem Eng J 383:12322810.1016/j.cej.2019.123228 ↗
90. Mirakabad FST et al (2019) Peptide dendrimers as valuable biomaterials in medical sciences. Life Sci 15(233)10.1016/j.lfs.2019.116754 ↗
91. Sreelekshmi, P. et al. (2020) Peptide dendrimer stabilized gold nanoparticles as sensors. Materials Today: Proceedings. https://doi.org/10.1016/j.matpr.2019.12.06010.1016/j.matpr.2019.12.060 ↗
92. Forier K et al (2014) Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J Control Release 190:607–62310.1016/j.jconrel.2014.03.055 ↗
93. Watkins R et al (2015) Natural product-based nanomedicine: recent advances and issues. Int J Nanomedicine 10:6055
94. Wang Y et al (2020) Biotin-decorated all-HPMA polymeric micelles for paclitaxel delivery. J Control Release 10(328):970–984. https://doi.org/10.1016/j.jconrel.2020.09.01310.1016/j.jconrel.2020.09.013 ↗
95. Tao J et al (2020) Toward understanding the prolonged circulation and elimination mechanism of crosslinked polymeric micelles in zebrafish model. Biomaterials 256:12018010.1016/j.biomaterials.2020.120180 ↗
96. Peres LB et al (2016) Solid lipid nanoparticles for encapsulation of hydrophilic drugs by an organic solvent free double emulsion technique. Colloids Surf B: Biointerfaces 140:317–32310.1016/j.colsurfb.2015.12.033 ↗
97. Surapaneni SG, Ambade AV (2022) Poly (N-vinylcaprolactam) containing solid lipid polymer hybrid nanoparticles for controlled delivery of a hydrophilic drug gemcitabine hydrochloride. RSC Adv 12(27):17621–1762810.1039/D2RA02845J ↗
98. Gallez A et al (2020) Liposomes and drug-in-cyclodextrin-in-liposomes formulations encapsulating 17beta-estradiol: An innovative drug delivery system that prevents the activation of the membrane-initiated steroid signaling (MISS) of estrogen receptor alpha. Int J Pharm 573:11886110.1016/j.ijpharm.2019.118861 ↗
99. Godara S et al (2020) Lipid-PLGA hybrid nanoparticles of paclitaxel: Preparation, characterization, in vitro and in vivo evaluation. Mater Sci Eng C 109:11057610.1016/j.msec.2019.110576 ↗
100. Trucillo P et al (2020) Production of liposomes loaded alginate aerogels using two supercritical CO2 assisted techniques. Journal of CO2 Utilization 39:10116110.1016/j.jcou.2020.101161 ↗